PCSK9 and atherosclerosis: With maximally tolerated LLM without use of PCSK9 inhibitors mean (95% CI) LDL-C was reduced to 3.1 (2.9, 3.3), which is much higher than the recommended levels in patients with established ASCVD or with FH, and especially in the combination of both.